



Applicant or Patentee: Philip C. Comp

Serial or Patent No.:

Attorney's

Docket No:

Filed or Issued:

July 24, 1992

OMRF128

For:

BLOCKADE OF PROTEIN C ACTIVATION REDUCES
MICROVASCULAR SURGICAL BLOOD LOSS

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) and 1.27(d)) - NONPROFIT ORGANIZATION

I hereby declare that I am an official empowered to act on
behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION: Oklahoma Medical Research
Foundation

ADDRESS OF ORGANIZATION: Oklahoma Medical Research
Foundation
825 N.E. 13th
Oklahoma City, Oklahoma 73104

TYPE OF ORGANIZATION

- [] UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION
- [] TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE
(26 USC 501(a) and 501(c)(3))
- [X] NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE
OF STATE OF THE UNITED STATES OF AMERICA
- [] WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE
SERVICE CODE (26 USC 501(a) and 501(c)(3) IF LOCATED
IN THE UNITED STATES OF AMERICA
- [] WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL
UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA
IF LOCATED IN THE UNITED STATES OF AMERICA
(NAME OF STATE:)
(CITATION OF STATUTE:)

I hereby declare that the nonprofit organization identified
above qualifies as a nonprofit organization as defined in 37 CFR
1.9(e) for purposes of paying reduced fees under section 41(a)

"Blockade of Protein C Activation Reduces
Microvascular Surgical Blood Loss"

Filed: July 24, 1992

VERIFIED STATEMENT CLAIMING SMALL ENTITY STATUS

and (b) of Title 35, United States Code with regard to the
invention entitled "Blockade of Protein C Activation Reduces Microvascular
Surgical Blood Loss" by Philip C. Comp
described in the specification filed July 24, 1992.

I hereby declare that rights under contract or law have been
conveyed to and remain with the nonprofit organization with
regard to the above-identified invention.

If the rights held by the nonprofit organization are not
exclusive, each individual, concern or organization having rights
to the invention is listed below* and no rights to the invention
are held by any person, other than the inventor, who could not
qualify as a small business concern under 37 CFR 1.9(d) or by any
concern which would not qualify as a small business concern under
37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

*NOTE: Separate verified statements are required from each named
person, concern or organization having rights to the invention
averring to their status as small entities. (37 CFR 1.27)

NAME: _____

ADDRESS: _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORG.

NAME: _____

ADDRESS: _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORG.

I acknowledge the duty to file, in this application or patent,
notification of any change in status resulting in loss of
entitlement to small entity status prior to paying, or at the
time of paying, the earliest of the issue fee or any maintenance

"Blockade of Protein C Activation Reduces
Microvascular Surgical Blood Loss"

Filed: July 24, 1992

VERIFIED STATEMENT CLAIMING SMALL ENTITY STATUS

fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING:

William G. Thurman, M.D.

TITLE IN ORGANIZATION:

Oklahoma Medical Research Foundation

ADDRESS OF PERSON SIGNING:

825 N.E. 13th Street, Oklahoma City, OK 73104

William G. Thurman, M.D.

July 23, 1992

SIGNATURE

DATE



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

DATE: 09/04/92
TO:
PATREA L. PABST
KILPATRICK & CODY
1100 PEACHTREE ST., SUITE 2800
ATLANTA, GA 30309-4530

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE U.S. PATENT AND TRADEMARK OFFICE ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT ASSIGNMENT PROCESSING SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT BRANCH, NORTH TOWER BUILDING, SUITE 10C35, WASHINGTON, D.C. 20231

ASSIGNOR:
COMP, PHILIP C.

DOC DATE: 07/23/92

RECORDATION DATE: 07/24/92 NUMBER OF PAGES 003 REEL/FRAME 6207/0990

DIGEST :ASSIGNMENT OF ASSIGNORS INTEREST

ASSIGNEE:
OKLAHOMA MEDICAL RESEARCH FOUNDATION
A CORP. OF OKLAHOMA
825 N.E. 13TH
OKLAHOMA CITY, OKLAHOMA 73104

SERIAL NUMBER 7-919219 FILING DATE 07/24/92
PATENT NUMBER ISSUE DATE 00/00/00


EXAMINER/PARALEGAL

ASSIGNMENT BRANCH
ASSIGNMENT/CERTIFICATION SERVICES DIVISION

LOCKETED: _____
BY: LFK
DATE: 9/25/92

"Blockade of Protein C Activation
Reduces Microvascular Surgical Blood Loss"
Filed: July 24, 1992
EXPRESS MAIL TRANSMITTAL LETTER


§ 1.10. The Express Mail Label No. appears in the heading of this paper which is attached to the application papers pursuant to 37 C.F.R. § 1.10(B).

The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Account No. 11-0855. To facilitate this process, applicants have enclosed a duplicate of this letter.

All correspondence concerning this application should be mailed to:

Patrea L. Pabst, Esq.
Kilpatrick & Cody
1100 Peachtree Street
Suite 2800
Atlanta, Georgia 30309-4530

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Date: July 24, 1992

Kilpatrick & Cody
1100 Peachtree Street
Suite 2800
Atlanta, Georgia 30309-4530
404/815-6508

REC-6207 FRANK 991

ASSIGNMENT

I, Philip C. Comp of 9805 Silver Lake Drive, Oklahoma City, Oklahoma 73162, in consideration of Five Dollars and other valuable consideration paid to me by Oklahoma Medical Research Foundation, a corporation of Oklahoma, having its principal place of business at 825 N.E. 13th, Oklahoma City, Oklahoma 73104, the receipt of which is hereby acknowledged, do hereby sell, assign and transfer unto said Oklahoma Medical Research Foundation, its successors and assigns, the entire interest for the United States of America and its territories and all foreign countries and jurisdictions, including all rights of priority under the International Convention for the Protection of Industrial Property in a certain invention or improvement in "Blockade of Protein C Activation Reduces Microvascular Surgical Blood Loss" described in an application filed herewith in the United States Patent and Trademark Office, and in all Letters Patent of the United States and its territories and all foreign countries and jurisdictions which may or shall be granted on said invention, or any parts thereof, or on said application, or any divisional, continuation, continuation-in-part, renewals, reissue or other applications based in whole or in part thereon. And I agree, for myself and my executor and administrator, with said corporation and its successors and assigns but at its or their expense or charges, hereafter to execute all applications, amended specifications, deeds or other instruments, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and in all other countries to said corporation, with specifications and claims in such form as shall be approved by the counsel of said corporation and to vest and confirm in said corporation, its successors and assigns, the legal title to all such patents.

And I do hereby authorize and request the Commissioner of Patents and Trademarks of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said corporation, its successors and assigns.

WITNESS my hand and seal this 23 day of July, 1992.

Philip C Comp
Philip C. Comp

State of Oklahoma)
County of Adair) ss.


Then personally appeared the above named Philip C. Comp and acknowledged the foregoing instrument to be his free act and deed, before me, this 23 day of July, 1992.

RECORDED
PATENT AND TRADEMARK
OFFICE

[Signature]
Notary Public
My Commission Expires Oct 2, 1995

JUL 24 1992

REF 6207 FRAM 992



40-581

July 24, 1992

AID

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Case Docket No.

OMRF1287/913219

Express Mail Label No. RB659096988US

Sir:

Transmitted herewith for filing is the patent application of

Inventor: Philip C. Comp

For: BLOCKADE OF PROTEIN C ACTIVATION REDUCES MICROVASCULAR
SURGICAL BLOOD LOSS

Enclosed are:

☒ 1 sheets of drawing.☒ An assignment of the invention to Oklahoma Medical Research Foundation☐ A certified copy of a☐ An associate power of attorney.☒ A verified statement to establish small entity status under 37 CFR 1.9 and 37 CFR 1.27.☐

application.

The filing fee has been calculated as shown below:

	(Col. 1)	(Col. 2)
FOR:	NO. FILED	NO. EXTRA
BASIC FEE		
TOTAL CLAIMS	17 -20 =	0
INDEP CLAIMS	2 -3 =	0
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIM PRESENTED		

*If the difference in Col. 1 is less than zero, enter "0"
in Col. 2

SMALL ENTITY		OR	OTHER THAN A SMALL ENTITY	
RATE	FEE		RATE	FEE
	\$ 345	OR		\$ 690
x10=	\$ 0	OR	x20=	\$
x36=	\$ 0	OR	x72=	\$
+ 110=	\$	OR	+ 220=	\$
TOTAL	\$345	OR	TOTAL	\$

☐ Please charge my Deposit Account No. _____ the amount of \$ _____. A duplicate copy of this sheet is enclosed.

☒ A check in the amount of \$ 345.00 to cover the filing fee is enclosed.

☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 11-0855. A duplicate copy of this sheet is enclosed.

☒ Any additional filing fees required under 37 CFR 1.16.

☒ Any patent application processing fees under 37 CFR 1.17.

☒ The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. 11-0855. A duplicate copy of this sheet is enclosed.

☒ Any patent application processing fees under 37 CFR 1.17.

☐ The issue fee set in 37 CFR 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR 1.311 (b).

☒ Any filing fees under 37 CFR 1.16 for presentation of extra claims.

Respectfully submitted,

93296135

160 MG 08/04/92 07919219

1 581

40.00 CK

Patrea L. Pabst, Reg. No. 31,284

BEST AVAILABLE COPY

REF 6207 FRANK 990